Aerie intends to initiate more trials and file NDA in 2016

Having initiated its fourth phase 3 trial for Rhopressa and its first phase 3 registration trial for Roclatan, Aerie pharmaceuticals is heading into 2016 with the intention of filing a new drug application for Rhopressa and beginning two more phase 3 trials for Roclatan, according to company press releases.Rhopressa is a triple-action IOP-lowering eye drop, and Roclatan is a fixed-dose combination of Rhopressa and latanoprost.